Breast Cancer Clinical Trial

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Summary

The primary objective is to examine the impact on progression-free survival of targeted therapy for breast cancer suggested by proteomic and genomic profiling.

View Full Description

Full Description

To explore the impact of targeted therapy for breast cancer suggested by proteomic and genomic profiling using RPMA, targeted resequencing, IHC analysis, WGS, RNA-seq, and Exome sequencing on progression-free survival. When a molecular target cannot be identified, the patient will be treated with a therapy selected on an empirical basis by the investigator/treating physician at the individual site and will be followed for survival status. Only available, FDA-approved agents will be used.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Life expectancy of >3 months
Diagnosis of metastatic breast cancer or an advanced gynecological malignancy with measurable disease
Age greater than or equal to 18 years
ECOG performance status of 0-1
Able to undergo two biopsies to obtain tissue with first biopsy required and second biopsy optional
Have failed or unable to tolerate previous treatment regimen
Adequate organ and bone marrow function as defined by ANC ≥ 1.5 x 109/L; Hgb 9 g/dL; platelets greater than 100 x 109/L; creatinine ≤ 1.5 mg/dL; bilirubin ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN (or ≤ 5 x ULN if due to underlying liver metastases); INR ≤ 1.5 x ULN (except in the case of anticoagulation therapy)

Exclusion Criteria:

Metastatic lesions that are not accessible to biopsy
Symptomatic CNS metastasis
Previous history of another malignancy within 5 years of study entry
Uncontrolled concurrent illness
Known HIV, HBB, and/or HCV infection
Pregnant or breast feeding or childbearing potential and not using adequate birth control

Study is for people with:

Breast Cancer

Study ID:

NCT02470819

Recruitment Status:

Withdrawn

Sponsor:

Avera McKennan Hospital & University Health Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Avera Cancer Institute
Sioux Falls South Dakota, 57105, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Study ID:

NCT02470819

Recruitment Status:

Withdrawn

Sponsor:


Avera McKennan Hospital & University Health Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider